Schizophrenia Drugs Market Analysis - Global Industry Size, Share, Trends and Forecast, 2018 – 2026

Introduction

Schizophrenia is a chronic and severe mental disorder of the central nervous system that affects 1.0% of the global population or seven out of 1,000 individuals upon how a person thinks, feels, and behaves. People with schizophrenia react like they have lost touch in reality. Although schizophrenia is not as common as other mental disorders, the symptoms can be very restricting.The symptoms such as thought disorders, hallucinations, inability to execute day-to day work are developed from a combination of chemical, genetic, and some environmental factors. Increasing consciousness among physicians and patients in the field of mental health, specifically schizophrenia is likely to increase the saturation of these drugs in the market. The peak age of commencement to this disease is mostly 20–28 years for males and 25–32 years for females. But now-a-days, children, teenagers, and all other age groups are been targeted with this disease. Currently, second-generation and third-generation antipsychotics capture substantial market share.

Market Dynamics

Factors such as large aging population, healthcare reforms, and increased health awareness are proving advantageous. Also, increased expenditure on availability of effective treatment methods and healthcare with demand for target specific treatments are primarily driving the market. Poor understanding about the exact disease causing mechanism needs advancement in technology with respect to the innovation in drug delivery mechanisms for the treatment of this incapacitating disorder..Globally the growing acceptance for long-acting injectable (LAI) antipsychotics, along with the arrival of unique treatments that achieve higher worth, will serve to spontaneous growth in the market over the forecast period. 

Market Classification and Overview

The market can be bifurcated on the basis of drug class, treatment, application, and geography. By drug class, schizophrenia drugs market can be segmented into first generation, second generation, third generation. Further second generation is segmented into Risperdal, Invega Geodon Seroquel, Zyprexa, Latuda ), Fanapt Saphris, Vraylar. Tthird generation is includes Abilify (Aripiprazole). By treatment, schizophrenia drugs market can be segmented into oral and injectable Antipsychotics. By application, schizophrenia drugs market can be segmented into schizophrenia, bipolar disorder, unipolar depression, and dementia, among others. On the basis of geography, the schizophrenia drugs market can be segmented into North America, Latin America, Europe, Middle East & Africa (MEA) and Asia-Pacific. Asia-Pacific is estimated to witness the fastest growth over the forecast period due to rising healthcare system development, social awareness regarding psychotic disorders, rising awareness about early diagnosis, availability of effective treatment and other associated disorders, such as anxiety, bipolar (mania), and major depression. Also, growing access and availability of medicines for required diagnosis and management of the symptoms of mental sicknesses is expected to raise the growth of the market in Asia-Pacific.

Report Coverage

Market Participants

Some of the key players involved in the supply of schizophrenia drug market include Johnson & Johnson, Bristol-Myers Squibb, AstraZeneca Plc, Sumitomo Dainippon Pharma Co., Ltd., Eli Lilly and Company, Alkermes Plc, Vanda Pharma Inc., Allergan Plc, Otsuka Pharmaceutical Co., Ltd and Lundbeck among others.

Market Segmentation

Market By Drug Class

• First Generation
• Second Generation
• Risperdal (Risperidone)
• Zyprexa (Olanzapine)
• Invega (Paliperidone)
• Seroquel (Quetiapine)
• Geodon (Ziprasidone)
• Latuda (Lurasidone)
• Fanapt (Iloperidone)
• Aristada (AripiprazoleLauroxil)
• Vraylar (Cariprazine)
• Saphris (Asenapine)
• Third Generation
• Abilify (Aripiprazole)

Market By Treatment

• Injectable Antipsychotics
• Oral Antipsychotics

Market By Application

• Schizophrenia
• Bipolar Disorder
• Unipolar Depression
• Dementia
• Others

Market By Geography

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • France
  • Germany
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Chile
  • Rest of LATAM
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • Rest of MEA